Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cindunistat in Knee Osteoarthritis
NCT00565812Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2007
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of cindunistat in osteoarthritis (OA) (3 arms), sponsored by Pfizer. Primary endpoints: Rate of Progression of Joint Space Narrowing at Month 24, Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Less Than or Equal to 2 at Month 24 and 1 more. Started Nov 2007; status: completed.
02
Drugs
cindunistat
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00565812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00565812.